FDA Approves MS CONTIN — Rhodes Pharmaceuticals LLC

Following the FDA's approval of expanded indications for Rhodes Pharmaceuticals LLC’s MS CONTIN (morphine sulfate) tablets, analysts project potential revenue growth in the chronic pain management sector as the market leader solidifies its dominance over established generic alternatives.